Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kodiak Sciences Inc.KOD · Entity 4388 | Director | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kodiak Sciences Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2036-06-29 | Direct | 17,731 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 17,731 · Balance 17,731 F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GILEAD SCIENCES, INC.
Report date May 08, 2007 · Filed May 15, 2007
Section 16 reporting ended · disclosed 2007-05-15. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Kronos Bio, Inc.
Report date June 20, 2025 · Filed June 20, 2025
Section 16 reporting ended · disclosed 2025-06-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 1
1 source rowRow 1 · 2025-06-20 · Other · Disposed 11,333 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.58 · Expires 2031-03-24 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-20 · Disposition to issuer · Disposed 41,200 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2031-06-21 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-20 · Disposition to issuer · Disposed 5,150 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.53 · Expires 2032-06-21 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-06-20 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2034-06-24 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 21:58 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 17,731 | $0.00 Strike: $38.96 | $0.00 |
DisclosureSEC source: 0001334505-26-000002 · form4-07022026_090725.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,731 Underlying: Common Stock · 17,731 shares Expires 2036-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:45 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001415889-25-019091 · form4-07022025_080736.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2026 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 20:15 UTC | Kronos Bio, Inc. KRON · Entity 78257 | Disposition to issuerStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001415889-25-017825 · form4-06202025_040607.xml · derivative · entry 6 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires 2034-06-24 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 20:15 UTC | Kronos Bio, Inc. KRON · Entity 78257 | Disposition to issuerStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-25-017825 · form4-06202025_040607.xml · derivative · entry 5 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires 2033-06-21 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 20:15 UTC | Kronos Bio, Inc. KRON · Entity 78257 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001415889-25-017825 · form4-06202025_040607.xml · derivative · entry 4 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2032-06-21 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 20:15 UTC | Kronos Bio, Inc. KRON · Entity 78257 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,150 | $0.00 Strike: $24.18 | $0.00 |
DisclosureSEC source: 0001415889-25-017825 · form4-06202025_040607.xml · derivative · entry 3 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,150 shares Expires 2031-06-21 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 20:15 UTC | Kronos Bio, Inc. KRON · Entity 78257 | Disposition to issuerStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $28.58 | $0.00 |
DisclosureSEC source: 0001415889-25-017825 · form4-06202025_040607.xml · derivative · entry 2 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,200 shares Expires 2031-03-24 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 20:15 UTC | Kronos Bio, Inc. KRON · Entity 78257 | OtherCommon Stock | 11,333 | $0.57 | $6,459.81 |
DisclosureSEC source: 0001415889-25-017825 · form4-06202025_040607.xml · nonDerivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2 · shares: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 22:26 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001415889-24-018665 · form4-07012024_100709.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-27 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 28, 2025 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:34 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001415889-24-018235 · form4-06262024_080639.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:30 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001209191-23-040593 · doc4.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2024 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 20:13 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001209191-23-039692 · doc4.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:32 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001209191-22-040860 · doc4.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2023 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 22, 2022 Filed Jun 29, 2022 20:15 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-22-039790 · doc4.xml · derivative · entry 2 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 22, 2022 Filed Jun 29, 2022 20:15 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantCommon Stock | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039790 · doc4.xml · nonDerivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,333 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:02 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 7,368 | $0.00 Strike: $93.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045064 · doc4.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,368 Underlying: Common Stock · 7,368 shares Expires 2031-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2022 or one (1) day prior to Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 01:22 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantStock Option (Right to Buy) · Derivative | 5,150 | $0.00 Strike: $24.18 | $0.00 |
DisclosureSEC source: 0001209191-21-042892 · doc4.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,150 Underlying: Common Stock · 5,150 shares Expires 2031-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 17:41 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantDirector Stock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $28.58 | $0.00 |
DisclosureSEC source: 0001209191-21-023181 · doc4.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2031-03-24 F1 · derivative.exercise_date: The shares subject to the option shall vest in three equal annual installments following the date of grant. Read SEC document |
| June 30, 2020 Filed Jul 3, 2020 01:14 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 5,417 | $0.00 Strike: $54.12 | $0.00 |
DisclosureSEC source: 0001209191-20-040831 · doc4.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,417 Underlying: Common Stock · 5,417 shares Expires 2030-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2021 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, provided the Reporting Person continues to serve as a member of the Issuer's Board through the applicable vesting date. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:43 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 8,855 | $0.00 Strike: $71.20 | $0.00 |
DisclosureSEC source: 0001209191-19-061390 · doc4.xml · derivative · entry 1 Yang Taiyin · CIK 0001334505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855 Underlying: Common Stock · 8,855 shares Expires 2029-12-16 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option vests on first anniversary of the grant date and 1/36th of the shares subject to the option vest on each month thereafter on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month), in each case, provided that the Reporting Person continues to serve as a member of the Board through the applicable vesting date. Read SEC document |
| May 02, 2007 Filed May 3, 2007 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,300 | $83.79 | $108,927.00 |
DisclosureSEC source: 0001179110-07-008969 · edgar.xml · nonDerivative · entry 6 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,381 Read SEC document |
| May 02, 2007 Filed May 3, 2007 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,600 | $83.74 | $133,984.00 |
DisclosureSEC source: 0001179110-07-008969 · edgar.xml · nonDerivative · entry 5 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,681 Read SEC document |
| May 02, 2007 Filed May 3, 2007 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,700 | $83.77 | $142,409.00 |
DisclosureSEC source: 0001179110-07-008969 · edgar.xml · nonDerivative · entry 4 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,281 Read SEC document |
| May 02, 2007 Filed May 3, 2007 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 14,500 | $83.75 | $1,214,375.00 |
DisclosureSEC source: 0001179110-07-008969 · edgar.xml · nonDerivative · entry 3 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,981 Read SEC document |
| May 02, 2007 Filed May 3, 2007 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $83.78 | $41,890.00 |
DisclosureSEC source: 0001179110-07-008969 · edgar.xml · nonDerivative · entry 2 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,481 Read SEC document |
| May 02, 2007 Filed May 3, 2007 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $83.76 | $33,504.00 |
DisclosureSEC source: 0001179110-07-008969 · edgar.xml · nonDerivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,981 Read SEC document |
| February 21, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,200 | $73.79 | $162,338.00 |
DisclosureSEC source: 0001179110-07-004569 · edgar.xml · nonDerivative · entry 6 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,381 Read SEC document |
| February 21, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $73.73 | $14,746.00 |
DisclosureSEC source: 0001179110-07-004569 · edgar.xml · nonDerivative · entry 5 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,581 Read SEC document |
| February 21, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,300 | $73.70 | $169,510.00 |
DisclosureSEC source: 0001179110-07-004569 · edgar.xml · nonDerivative · entry 4 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,781 Read SEC document |
| February 21, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $73.78 | $29,512.00 |
DisclosureSEC source: 0001179110-07-004569 · edgar.xml · nonDerivative · entry 3 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,081 Read SEC document |
| February 21, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $73.74 | $22,122.00 |
DisclosureSEC source: 0001179110-07-004569 · edgar.xml · nonDerivative · entry 2 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,481 Read SEC document |
| February 21, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 14,600 | $73.71 | $1,076,166.00 |
DisclosureSEC source: 0001179110-07-004569 · edgar.xml · nonDerivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,781 Read SEC document |
| February 06, 2007 Filed Feb 8, 2007 00:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,900 | $70.22 | $1,116,498.00 |
DisclosureSEC source: 0001179110-07-003135 · edgar.xml · nonDerivative · entry 2 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,381 Read SEC document |
| February 06, 2007 Filed Feb 8, 2007 00:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,100 | $70.24 | $287,984.00 |
DisclosureSEC source: 0001179110-07-003135 · edgar.xml · nonDerivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,281 F1 · balance_after: Amount of Securities Beneficially Owned Following Reported Transaction (s) (Table 1, Col. 5) includes 720 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 30, 2006. Read SEC document |
| January 22, 2007 Filed Jan 24, 2007 21:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $65.58 | $0.00 |
DisclosureSEC source: 0001179110-07-001858 · edgar.xml · derivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2017-01-22 F1 · derivative.exercise_date: Options vest over a five year period beginning 1/22/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 1/22/2012. Read SEC document |
| July 26, 2006 Filed Jul 28, 2006 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $61.89 | $0.00 |
DisclosureSEC source: 0001179110-06-015730 · edgar.xml · derivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2016-07-26 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on July 26, 2007, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on July 26, 2011. Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 9,891 | $61.10 | $604,340.10 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 14 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,661 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,800 | $61.11 | $109,998.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 13 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,552 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,500 | $61.13 | $91,695.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 12 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,352 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,999 | $61.14 | $244,498.86 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 11 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,852 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $61.19 | $6,119.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 10 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,851 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $61.18 | $12,236.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 9 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,951 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $61.20 | $12,240.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 8 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,151 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $61.21 | $30,605.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 7 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,351 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 310 | $61.22 | $18,978.20 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 6 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,851 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $61.23 | $12,246.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 5 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,161 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $61.24 | $6,124.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 4 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,361 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 600 | $61.25 | $36,750.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 3 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,461 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $61.27 | $6,127.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 2 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,061 Read SEC document |
| February 22, 2006 Filed Feb 24, 2006 15:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $61.28 | $30,640.00 |
DisclosureSEC source: 0001179110-06-004677 · edgar.xml · nonDerivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,161 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.